Ewing sarcoma (EWS) is a soft tissue and bone tumor that occurs primarily in adolescents and young adults. In most cases of EWS, the chimeric transcription factor, EWS-FLI1 is the primary oncogenic driver. The epigenome of EWS cells reflects EWS-FLI1 binding and activation or repression of transcription. Here, we demonstrate that EWS-FLI1 positively regulates the expression of proteins required for serine-glycine biosynthesis and uptake of the alternative nutrient source glutamine. Specifically, we show that EWS-FLI1 activates expression of PHGDH, PSAT1, PSPH, and SHMT2. Using cell-based studies, we also establish that EWS cells are dependent on glutamine for cell survival and that EWS-FLI1 positively regulates expression of the glutamine transporter, SLC1A5 and two enzymes involved in the one-carbon cycle, MTHFD2 and MTHFD1L. Inhibition of serine-glycine biosynthesis in EWS cells impacts their redox state leading to an accumulation of reactive oxygen species, DNA damage, and apoptosis. Importantly, analysis of EWS primary tumor transcriptome data confirmed that the aforementioned genes we identified as regulated by EWS-FLI1 exhibit increased expression compared with normal tissues. Furthermore, retrospective analysis of an independent data set generated a significant stratification of the overall survival of EWS patients into low-and high-risk groups based on the expression of PHGDH, PSAT1, PSPH, SHMT2, SLC1A5, MTHFD2, and MTHFD1L. In summary, our study demonstrates that EWS-FLI1
reprograms the metabolism of EWS cells and that serine-glycine metabolism or glutamine uptake are potential targetable vulnerabilities in this tumor type.
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| INTRODUCTION
Cancer cells must activate or enhance metabolism to satisfy the energy and biosynthetic needs of rapid proliferation and growth in nutrient and oxygen-poor environments. Alterations in metabolic processes used by cancer cells include high rates of glycolysis and cytosolic lactic acid fermentation (the Warburg effect), or the utilization of non-essential amino acids as alternate nutrient sources or as metabolites. Examples of amino acids some tumor types use to support their increased metabolic requirements include glutamine, serine, or glycine (reviewed in ref. [1] [2] [3] [4] [5] ).
The serine-glycine biosynthesis pathway ( Figure 1A ) involves the conversion of 3P-glycerate to 3P-hydroxy-pyruvate by phosphoglycerate dehydrogenase (PHGDH), the conversion of 3P-hydroxy-pyruvate to 3P-serine by phosphoserine aminotransferase 1 (PSAT1), and phosphoserine phosphatase (PSPH) converts 3P-serine to serine.
Serine hydroxymethyltransferase 1 (SHMT1) and serine hydroxymethyltransferase 2 (SHMT2) catalyze the conversion of serine to glycine in the cytosol and mitochondria, respectively. Serine-glycine biosynthesis is not only linked to the generation of macromolecules like nucleotides, lipids, and proteins, but it also regulates cellular redox homeostasis and methylation reactions via methionine and one-carbon folate cycles. 1, 6 Recent studies of melanoma, and breast and lung cancers revealed genetic changes that result in the utilization of the serine-glycine biosynthesis pathway to support cell growth. [7] [8] [9] The genetic basis for activation of serine-glycine biosynthesis pathway in cancer includes amplification of the PHGDH locus or its transcriptional deregulation. Overall, 16% of all cancers exhibit a gain of the chromosome 1p12 region that contains the PHGDH locus, 7, 10 including a sizeable proportion of melanomas and breast cancers. 7, 8 Furthermore, approximately 70% of estrogen receptor-negative breast cancers overexpress PHGDH protein.
In non-small cell lung cancer (NSCLC), the transcription factor NRF2 alters the expression of ATF4 that in turn upregulates PHGDH. 9 Importantly, the inhibition of PHGDH or de novo serine-glycine biosynthesis in cell lines with elevated PHGDH expression results in decreased cell viability, indicating that these cells are dependent on serine-glycine biosynthesis for cell survival. [7] [8] [9] 11 The genetic reprogramming of some cancer types to make use of glutamine as an alternative nutrient source includes increased expression of proteins that act as transporters of amino acids, such as SLC1A5 (ASTC2), [12] [13] [14] or the upregulation of enzymes that catalyze the metabolism of glutamine, for example, glutaminase. 15 Proliferating cancer cells use glutamine as a nitrogen donor for the synthesis of nucleotide precursors, and following the conversion to glutamate, the generation of the amino acids alanine and aspartate. 4, 16, 17 The conversion to glutamate also enables cells to use glutamine as a carbon source for the production of α-ketoglutarate through the activity of glutamine dehydrogenase or an aminotransferase, including PSAT1. 4, 16, 17 Strategies to exploit the dependence of some tumor types on glutamine that are under development include the use of glutamine transport or enzyme inhibitors. [18] [19] [20] Ewing sarcoma (EWS), a soft tissue and bone tumor, primarily occurs in adolescents and young adults. In most cases of EWS, the initiating genetic event involves a chromosomal translocation that fuses the 5′ end of the EWSR1 gene to the 3′ end of a member of the ETS (E26-transformation specific) family of genes, FLI1. The EWS-FLI1 fusion gene expresses an oncogenic chimeric transcription factor that deregulates the expression of many hundreds of genes. The epigenome of EWS cells reflects the changes in the regulatory state of genes associated with EWS-FLI1 binding and activation or repression of transcription. [21] [22] [23] Examples of genes linked to the oncogenic activity of EWS-FLI1 include other regulators of transcription such as NR0B1, [24] [25] [26] GLI1, [27] [28] [29] and EZH2, 30, 31 and enzymes such as PARP1. 32 Few studies have assessed the regulation of metabolism by EWS-FLI1, though one study showed that EWS-FLI1 deregulates tryptophan metabolism by suppressing the expression of TDO2, 33 and a second recent study demonstrated EWS-FLI1 regulates proteins involved in serine-glycine biosynthesis. 34 In our study, we confirm EWS-FLI1 controls the expression of the major enzymes involved in de novo serine-glycine biosynthesis but extend those earlier findings by establishing that EWS-FLI1 regulates the expression of these genes directly. Furthermore, we show that EWS-FLI1 also regulates the glutamine transporter, SLC1A5/ASCT2, and enzymes involved in the one-carbon cycle. Moreover, we demonstrate that EWS cells are sensitive to inhibition of PHGDH function and preferentially depend on exogenous glutamine rather than serine and glycine for cell proliferation and are thus susceptible to glutamine antagonism. Importantly, EWS primary tumors exhibit deregulation of these critically interrelated metabolic genes. Our study suggests that it may be possible to exploit the EWS-FLI1
reprogramming of EWS cell metabolism as a therapeutic vulnerability. 38 The acquisition and molecular profiling of EWS primary tumor samples and normal tissues were described previously. 39 All specimens for sequencing were obtained from patients with appropriate consent from the local institutional review board in accordance with the Children's Oncology Group and the National Cancer Institute; see the previous study for additional details. 39 The complete dataset is available at dbGaP Study Accession Number: phs000768.v2.p1.
We collected ChIP-seq data from a published study, 40 and generated coverage density maps (tiled data files) by counting the number of reads that mapped to each 25 base pair (bp) window 
| Immunoblotting
We prepared total lysates from cells post-treatment using cell extraction buffer (FNN0011, Thermo Fisher Scientific) and performed immunoblotting using the following antibodies: anti-ACTB (sc-47778)
from Santa Cruz Biotechnology, Santa Cruz, CA; anti-ATF4 
| Cell starvation experiments
We grew cells in their respective complete medium containing 10% 
| Metabolism assays and ROS analysis
We assayed α-ketoglutarate, glycine, formate, GSH/GSSG and NADP/NADPH ratios, pyruvate, and hexokinase activity using the respective colorimetric or fluorometric assays (BioVision, Milpitas, CA) as per the manufacturer's instructions generating standard curves for each experiment as specified in the supplied protocols.
We estimated protein concentrations and pre-normalized metabolic levels or enzyme activity by using equal amounts of protein for each measurement and assayed at least three biological replicas in each experiment using an Ensight plate reader (Perkin Elmer, Waltham, MA) for all assays. We measured the generation of ROS was using fluorescent dye carboxy-H 2 DCFDA (Thermo Fisher Scientific)
as per the manufacturer's instructions and analyzed the flow cytometry data using FlowJo software (Version 10.0.7) (FlowJo, LLC, Ashland, OR).
| Functional and 3D spheroid assays
We measured caspase activation and cell viability using the CaspaseGlo 3/7 and the CellTiter-Glo® Luminescent assay systems respectively (Promega) per manufacturer's instruction using at least three biological replicas of each treatment.
We performed spheroid studies using a magnetic 3D-spheroid system from Nano3D Biosciences, Inc (Houston, TX). Briefly, we magnetized cells before spheroid assembly using magnetic nanoparticles as per manufacturer's instructions (NanoShuttle-PL, Nano3D Biosciences). Following overnight treatment with magnetic nanoparticles, cells were trypsinized, counted, and plated in replenished media at a concentration of 250 cells/well in 384-well ultra-low attachment (ULA) flat bottom plates (Greiner Bio-one #781976). For spheroid formation, we placed the plates on top of a magnetic spheroid drive (Nano3D Biosciences). To facilitate complete media changes, after 48 h in culture, we placed the plates on a magnetic holding drive (Nano3D Biosciences) that retains the spheroids within each well and replaced the growth media. We cultured spheroids for an additional 24 to 48 h in complete or nutrient depleted media. We analyzed cell viability (48 h) using the CellTiter-Glo® reagent (Promega) supplemented with 20% trypsin to help disrupt the spheroids. We measured caspase activation (24 h) using CaspaseGlo 3/7 (Promega). During incubation with the CaspaseGlo 3/7 reagent, we disrupted the spheroids structures by pipetting. We obtained images of spheroids using a Celigo microwell image cytometer and software (Nexcelom Bioscience, MA).
We performed spheroid-based clonogenic assays as described by Senkowski et al. 41 Briefly, we plated TC32 cells in 384-well ULA round bottom plates, and cultured spheroids for 96 h followed by 72 h of drug treatment. After drug treatment, we collected each spheroid, dispersed the cells that form the spheroid, and plated the resulting single cell suspension into the well of a six-well plate.
We incubated cells for seven days in the drug-free medium, after which we fixed cell colonies with 100% ethanol and stained with crystal violet (0.04% crystal violet, 2% methanol in PBS). We performed each experiment in biological triplicate. We determined the number of colonies using a Celigo microwell image cytometer and software. ATF4 is a key regulator of amino-acid biosynthesis, and in non-small cell lung carcinoma it is the effector transcription factor that activates expression of the serine-glycine pathway. 9 To determine whether ATF4 functions as the regulator of serine-glycine biosynthesis genes in EWS cells, we silenced ATF4 (siATF4) in TC32 and SKMNC cells. Depletion of ATF4 in EWS cells did not affect PHGDH, PSPH, PSAT1, or SHMT2 mRNA levels ( Figure S4B ). Furthermore, silencing of EWS-FLI1 (siFLI1) had no significant effect on ATF4 expression ( Figure S4C ). We thus hypothesized that EWS-FLI1 regulates the expression of multiple serine-glycine biosynthesis genes directly. To test this hypothesis, we first interrogated reported EWS-FLI1 ChIP-seq data generated using A673 EWS cells. 40 Published data indicated substantial binding of EWS-FLI1 at sites within the regulatory regions of PHGDH, PSAT1, PSPH, and SHMT2 ( Figure 1B) . To validate the binding of Figures 1H and S4D ). Together, our data suggest that EWS-FLI1 is a direct driver of the transcriptional regulation of multiple enzymes involved in serine-glycine biosynthesis.
| EWS cells use glutamine as a nutrient source
We next hypothesized that the activation of de novo serine-glycine synthesis should enable EWS cells to proliferate in the absence of exogenous sources of serine or glycine. To test that hypothesis, we measured the viability of TC32 and SKNMC cells after 24 or 48 h of growth in control medium or medium depleted of serine and glycine. 
| EWS cells uptake extracellular glutamine via the glutamine transporter SLC1A5
To determine whether EWS-FLI1 regulates the expression of genes involved in glutamine metabolism or glutamine uptake directly, we To obtain evidence as to whether EWS-FLI1 regulates one or both SLC1A4 and SLC1A5 directly, we first confirmed the effects of silencing EWS-FLI1 on their expression using qPCR analysis. qPCR analysis detected a small decrease in SLC1A4 expression following depletion of EWS-FLI1, but a more substantial decrease in the expression of SLC1A5 ( Figure 3B ) that we also observed in SKMNC Unpaired adjusted t-test ***P < 0.001 n.s. = non-significant.; (C and E) Two-way ANOVA (adjusted P-value) ***P < 0.001; (D) Unpaired t-test, corrected for multiple comparisons ***P < 0.001 cells ( Figure S6C) and at a protein level ( Figure S6D ) and so we focused our next studies on this glutamine transporter. Using published A673-ChIP-seq data, 40 we identified a potential regulatory sequence within the SLC1A5 gene bound by EWS-FLI1.
ChIP-PCR-based analysis of this DNA region in TC32 cells
showed decreased binding of EWS-FLI1 following the silencing of (Figures 3D and S6E ). We were unable to identify any regulatory sequence within the SLC1A4 gene bound by EWS-FLI1.
EWS-FLI1
To assess whether EWS cells depend on SLC1A5 function for serine-glycine biosynthesis, we assayed intracellular glycine levels in EWS cells depleted of EWS-FLI1 ( Figure 3E ) or exposed to the SLC1A5 inhibitor, L-γ-Glutamyl-p-nitroanilide (GPNA, 1 mM). 12, 43, 44 Both the decreased expression of EWS-FLI1 and the addition of GPNA lowered the intracellular levels of glycine in TC32 and SKNMC cells, suggesting that SLC1A5 positively modulates intracellular levels of glycine. ( Figure 4C ). In contrast, reduced expression of EWS-FLI1 did not alter pyruvate levels or hexokinase enzyme activity, suggesting that when grown in standard cell culture conditions the activity of the fusion oncoprotein has little or no direct effect on glycolysis or glucose metabolism ( Figures S7A and S7B ). To validate that the generation of α-ketoglutarate occurs as a byproduct of serine-glycine biosynthesis, we silenced PHGDH in TC32 and SKNMC cells and measured α-ketoglutarate levels ( Figure 4D ).
EWS cells depleted of PHGDH exhibited a significant reduction in total α-ketoglutarate levels ( Figure 4D) , and we observed similar effects when we treated TC32 cells with increasing concentrations of the PHGDH inhibitors CBR5884 or NCT503 ( Figure 4E ).
Our results suggest that EWS-FLI1-mediated serine-glycine biosynthesis generates the anaplerotic pool of α-ketoglutarate needed for EWS cell proliferation.
3.5 | The EWS-FLI1 oncoprotein regulates the expression of genes required for the mitochondrial one-carbon cycle
Serine acts as the primary carbon donor for the mitochondrial folate cycle, donating its side-chain carbon to folate, consequently generating glycine and methylene-tetrahydrofolate (mTHF) as a part of the one-carbon cycle ( Figure 5A ). 3, 6 Since folate intermediates cannot cross the mitochondrial membrane without cleavage to formate, we measured formate levels as a readout of one-carbon cycle activity in 5F , and S7D) and we also observed reduced binding of EWS-FLI1
to sites within the promoters of MTHFD2 and MTHFD1L
( Figures 5G and S7E ). Finally, we expanded a previous assessment that examined the overall survival of patients with EWS correlated with expression of several metabolic genes (PHGDH, PSPH, SHMT2, and MTHFD2) [34] , to include the additional metabolic genes identified by our study as regulated by EWS-FLI1. Analysis of a deposited EWS dataset generated by Savola and co-workers 48 using the SurvExpress tool 49 showed highly significant separation (hazard ratio 8.99; P = 1.128 × 10 Together, these data suggest that the deregulation of multiple metabolism genes supports the growth of EWS tumors.
| DISCUSSION
Here, we report that the fusion transcription factor EWS-FLI1 regulates the expression of multiple enzymes required for de novo serine-glycine biosynthesis, specifically PHGDH, PSAT1, PSPH, and SHMT2. We also demonstrate that EWS-FLI1 regulates expression of the amino acid transporter SLC1A5, and two enzymes that function in the mitochondrial one-carbon cycle, MTHFD2 and MTHFD1L.
Depletion of EWS-FLI1, or inhibition of serine-glycine biosynthesis through the application of PHGDH inhibitors, results in ROS accumulation, DNA damage, and apoptotic cell death ( Figure 8 ).
Our study complements and extends a recent report by Tanner and colleagues 34 that also described the regulation of de novo serineglycine biosynthesis by EWS-FLI1. Tanner and colleagues presented data using shRNA-based silencing of EWS-FLI1 that indicated EWS-FLI1
regulates PHGDH, PSAT1, and PSPH expression, and that depletion of EWS-FLI1 decreases the expression of SHMT1/2. Importantly,
Tanner and co-workers show PHGDH expression is high in EWS primary tissue samples and that overall survival also correlates with PHGDH expression. Our study confirms these findings ( Figure 1B-F) , and further shows using ChIP-PCR analysis that EWS-FLI1 regulates the expression of PHGDH, PSAT1, and PSPH directly ( Figure 1G ). Interestingly, we demonstrated through nutrient deprivation and inhibitor studies that EWS cells exhibit little dependence on glucose in comparison with control cells (Figures 2B and S3B ). We also observed no changes in total pyruvate or hexokinase levels ( Figure S5A and B) following depletion of EWS-FLI1. Our results differ from previously published findings. Tanner and colleagues reported an increased | 1355 utilization of glucose by glycolysis following depletion of EWS-FLI1 that they linked to the derepression of the expression of the hexokinase enzyme. 34 A separate study showed glucose deprivation in combination with hypoxia affected the viability of EWS cells. 54 We speculate that these divergent results reflect the use of different growth conditions and assays, but future studies will be required to clarify the reasons for these differences.
The additional catalytic functions of PSAT1 and SHMT2 link the serine-glycine biosynthesis pathway to other metabolic pathways.
PSAT1, the second enzyme in the serine-glycine biosynthesis pathway also catalyzes the generation of α-ketoglutarate, a key metabolite in TCA cycle, from glutamate. Using gain-or loss-of-function studies we
show EWS-FLI1 regulates α-ketoglutarate levels and importantly, inhibition of PHGDH activity recapitulates the decrease in α- 
